Leonard Reyno - 10 Jul 2026 Form 4 Insider Report for C4 Therapeutics, Inc. (CCCC)

Reporting relationship: Chief Medical Officer
Issuer ticker: CCCC
Reported as of: 10 Jul 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 13 Jul 2026, 16:33:49 UTC
Prior SEC filing: 18 Feb 2026
Source filing: View source filing
Reporting owner signature: /s/ Shagha Russell, Attorney-in-Fact

Key filing fact

Leonard Reyno filed Form 4 for C4 Therapeutics, Inc. (CCCC) on 13 Jul 2026.

Key facts

This page summarizes Leonard Reyno's Form 4 filing for C4 Therapeutics, Inc. (CCCC).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 13 Jul 2026, 16:33.

Change

Previous filing in this sequence was filed on 18 Feb 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001528716 Primary reporting owner

REYNO LEONARD

Relationship: Chief Medical Officer
Address: C/O C4 THERAPEUTICS, INC., 490 ARSENAL WAY #120, WATERTOWN
Signature: /s/ Shagha Russell, Attorney-in-Fact
Signature date: 13 Jul 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CCCC transaction

Common Stock

Options Exercise

Transaction value
Shares: +15,325
Change %: +4.2%
Price: $0.000000^*
Shares after: 379,803
Date: 10 Jul 2026
Ownership: Direct
Footnotes: F1

CCCC transaction

Common Stock

Tax liability

Transaction value
Shares: -7,397
Change %: -1.9%
Price: $4.06^*
Shares after: 372,406
Date: 10 Jul 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Reflects the acquisition of shares of Common Stock upon vesting of previously disclosed grants of restricted stock units ("RSUs"). The grant of RSUs was initially reported in Table I of the Form 4 filed by the Reporting Person on July 12, 2023.

Footnote F2

Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting and settlement of RSUs and does not represent a sale by the Reporting Person.